Entry Point Capital, LLC Roivant Sciences Ltd. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Entry Point Capital, LLC holds 1,148 shares of ROIV stock, worth $13,707. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,148Holding current value
$13,707% of portfolio
0.02%Shares
2 transactions
Others Institutions Holding ROIV
# of Institutions
308Shares Held
496MCall Options Held
989KPut Options Held
1.15M-
Sb Investment Advisers (Uk) LTD London, X071.4MShares$852 Million6.97% of portfolio
-
Viking Global Investors LP69.2MShares$826 Million2.91% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$797 Million72.99% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$422 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.3MShares$350 Million0.02% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.41B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...